DV
Dividend Vision

CSTL — Castle Biosciences Inc

Castle Biosciences Inc (CSTL)

Total return is 38.4% over the past 7.1 years, 148.2 points behind SPY at 186.6%. Its deepest 1-year drawdown was 57.8%.

Castle Biosciences Inc is an individual biotech stock that provides diagnostic testing and treatment planning services for cancer patients, primarily focused on melanoma and other solid tumors. As a single equity holding rather than a diversified fund, it does not have a distribution rate, expense ratio, or regular dividend distributions. The stock appeals primarily to growth-oriented investors seeking exposure to precision medicine and oncology diagnostics, rather than to income-focused investors.

CSTL key facts

Asset type
Stock
Asset class
Equity
Inception date
07/25/2019
Last close
$29.62
Market cap
$732,771,648
Average volume
264212.0
Beta
0.996
Payout ratio
0.0
Forward P/E
0.0
EPS
$-0.42